Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (752)	3/10/2000 5:08:00 PM
From: Daveyk	Read Replies (1) \| Respond to of 1298

Man that hurts Bosco.It may have been the bottom where I sold but you know the many mistakes I've made over the years.You're right about the story and I'm sure the long termers will be well rewarded.I don't think I've ever held such a volatile stock before. Best,Dave

To: Bosco who wrote (752)	3/11/2000 9:58:00 PM
From: GregS	Read Replies (3) \| Respond to of 1298

CEGE's ownership of ABGX is 19%, not 12% as previously stated. Specifically, CEGE owns 3,392,034 shares of ABGX, which means each share of CEGE share is worth over $36 based just on ownership of ABGX. Cash on hand adds another $1.25 to each share. CEGE's core business, research, and patents are more difficult to value, but are probably worth anoter $20 - $60 per share. CEGE should have found a bottom now based on valuation. The conference this weekend should help as well. I look for analyst coverage to get this stock moving back up.